• Régis Peffault de Latour, Véronique Fremeaux-Bacchi, Raphaël Porcher, Aliénor Xhaard, Jérémie Rosain, Diana Cadena Castaneda, Paula Vieira-Martins, Stéphane Roncelin, Paula Rodriguez-Otero, Aurélie Plessier, Flore Sicre de Fontbrune, Sarah Abbes, Marie Robin, and Gérard Socié.
• Service d'Hématologie Greffe, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Paris, France; Equipe d'accueil 3518, Paris, France;
• Blood. 2015 Jan 29; 125 (5): 775-83.

AbstractParoxysmal nocturnal hemoglobinuria (PNH) is characterized by intravascular hemolysis, which is effectively controlled with eculizumab, a humanized monoclonal antibody that binds complement protein 5 (C5). The residual functional activity of C5 can be screened using a 50% hemolytic complement (CH50) assay, which is sensitive to the reduction, absence, and/or inactivity of any components of the classical and terminal complement pathway. Little data exist on complement blockade during treatment. From 2010 to 2012, clinical data, hemolysis biomarkers, complement assessment, and free eculizumab circulating levels were systematically measured immediately before every injection given to 22 patients with hemolytic PNH while receiving eculizumab therapy. During the study, 6 patients received ≥1 red blood cell transfusion. Lack of detectable CH50 activity (defined by CH50 ≤ 10% of normal values) was found in 184 samples (51%) and was significantly associated with lower lactate dehydrogenase levels (P = .002). Low levels of circulating free eculizumab (<50 µg/mL) correlated with detectable CH50 activity (CH50 > 10%; P = .004), elevated bilirubin levels (P < .0001), and the need for transfusions (P = .034). This study suggests that both CH50 activity and circulating free eculizumab levels may help physicians to manage PNH patients receiving eculizumab. © 2015 by The American Society of Hematology.

41 keywords...

hide…